This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/18/2026
Doses of paliperidone palmitate extended-release injectable suspension may be expressed in milligram equivalents of paliperidone (active moiety) or milligrams of paliperidone palmitate. Dosage information in this response has been converted to milligrams of paliperidone palmitate to reflect the commercially available dosage strengths in the United States. The conversion factor mg eq to mg is 1.56.
Douglas et al (2018)1 reported on a 56-year-old African American male who was involuntarily admitted to the Veterans Affairs medical center due to paranoia, increased outbursts, and aggression. Past medical history included hypertension, hyperlipidemia, vitamin D deficiency, TBI from a motor vehicle accident and seizure disorder post-TBI (treated with divalproex DR 750 mg twice daily and topiramate 200 mg twice daily). The patient's seizures were uncontrolled, but valproic acid levels measured on admission showed compliance with treatment. Psychotic disorder due to another medical condition with delusions was ruled out. The patient was previously admitted for behavioral disturbances secondary to TBI. During his second stay, he was given risperidone up to 6 mg/day, but was tapered prior to discharge due to medication refusal.
Upon admission, the patient’s behavior was attributed to post-TBI psychosis and he was started on risperidone 1mg daily; however, this treatment was consistently refused. The patient remained paranoid, argumentative, and delusional during the first 2 weeks of his hospital stay. He experienced a seizure on hospital day (HD) 2, but refused medication adjustment because he was paranoid that medical staff were plotting in an attempt to keep him hospitalized.1
On HD 15, INVEGA SUSTENNA 234 mg was administered to the patient. Based on daily interviews by the attending psychiatrist and nursing reports, there was an improvement in symptoms within a week of the first injection. The patient’s paranoia lessened, and he accepted the next injections of INVEGA SUSTENNA 156 mg on HDs 22 and 50. The patient experienced a second seizure on HD 24 and a possible third seizure on HD 62. It is unknown whether this patient’s seizures were medication-related due to his history of uncontrolled epilepsy. No other acute neurological, psychiatric, or adverse medication events were documented.1
Ghailani et al (2026)2 reported the case of a 19-year-old male with a history of severe TBI sustained at age 9 years due to a car accident. The injury resulted in intracranial bleeding, seizures, coma, a vegetative/unresponsive wakefulness state, and a minimally conscious state, requiring prolonged hospitalization and rehabilitation. Following initial recovery, the patient developed a prolonged post-traumatic confusional state characterized by inattention, disorientation, agitation, impulsivity, aggression, and behavioral dysregulation.2
Approximately 1 year after the injury, the patient was referred to psychiatric evaluation. Initial pharmacologic treatments included risperidone (up to 0.25 mg 3 times daily) and methylphenidate 10 mg, both of which provided limited benefit and were later discontinued. At the age of 15 years, repeat evaluation demonstrated persistent post-traumatic confusional state. Treatment with olanzapine 5 mg daily, titrated to 10 mg daily, was initiated and later discontinued because of excessive sedation. A subsequent trial of aripiprazole 7.5 mg daily was limited by poor adherence and worsening behavioral symptoms.2
At age 17 years, the patient presented to the emergency department with severe agitation and aggression, requiring intramuscular haloperidol for behavioral control. Due to continued nonadherence to oral treatments, INVEGA SUSTENNA was initiated at 156 mg and subsequently increased to 234 mg monthly, with adjunct risperidone 2 mg administered in the night. During approximately 2 years of follow-up, family members reported reductions in aggression, improved behavioral stability, improved impulse control, and improved engagement in structured activities. Functional status improved from Level IV (confused-agitated) to Level VIII (purposeful-appropriate) on the Rancho Los Amigos Levels of Cognitive Functioning Scale.2
At age 19 years, neuropsychological evaluation demonstrated average intellectual ability with persistent executive dysfunction. Adverse events reported during treatment included weight gain and asymptomatic hyperprolactinemia. No extrapyramidal symptoms, clinically significant QTc prolongation, treatment-related seizure recurrence, or hematologic adverse events were reported.2
| 1 | Douglass AR, Smyth U. A case report of guardian-consent forced paliperidone palmitate for behavioral disturbance due to traumatic brain injury. Ment Health Clin. 2018;8(3):155-158. |
| 2 |
Would you like to clear and leave your conversation? Message history will be lost.